Morgan Stanley analysts have estimated that Lilly’s GLP-1 pill could bring in as much as $40 billion in annual sales by 2033.

(CNN)– Eli Lilly says it will file for regulatory approval for its GLP1 weight loss pill called Orforglipron. The latest results from a trial of the medication offer enough information for the ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

U.S. pharmaceutical giant Eli Lilly (LLY) says it is preparing for the approval and launch of its new weight loss pill ...

GLP-1 drugs may lower the risk of some obesity-related cancers, according to an observational study of people who were ...

There's nothing like a successful clinical trial of a high-potential medicine to blast a pharmaceutical company 's stock price higher. That was the dynamic behind Eli Lilly 's (NYSE: LLY) nearly 6% ...

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory ...

Eli Lilly says its experimental GLP-1 pill, orforglipron, helped people with diabetes lose weight and lower A1C levels.

Eli Lilly says its weight loss pill orforglipron could win approval this year after a trial showed over 10% weight loss in ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...